POINT Biopharma Global (PNT) News Today → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free PNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInvesting in biopharma innovation: Can you stay one step ahead?bloomberg.com - April 8 at 8:10 PMDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Companybusinesswire.com - January 8 at 2:32 PMLilly Completes Acquisition of POINT Biopharmafinance.yahoo.com - December 27 at 9:30 AMmarketbeat.com - December 27 at 6:01 AMPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition Prospectsmarkets.businessinsider.com - December 22 at 8:49 AMBrookline Capital Downgrades POINT Biopharma Global (PNT)msn.com - December 22 at 8:49 AMPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and Forecastbenzinga.com - December 22 at 12:13 AMPOINT Biopharma Global (NASDAQ:PNT) Receives Hold Rating from Brookline Capital Managementmarketbeat.com - December 21 at 8:22 AMLilly extends tender offer for POINT Biopharma to Dec. 22msn.com - December 18 at 3:32 PMWhy POINT Biopharma Global Is At Least A Hold On Disappointing Readoutseekingalpha.com - December 18 at 3:32 PMPOINT Biopharma Global Sees Unusually High Options Volume (NASDAQ:PNT)marketbeat.com - December 18 at 1:39 PMLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Resultsmarkets.businessinsider.com - December 18 at 10:32 AMPOINT Biopharma Global Inc. (NASDAQ:PNT) Short Interest Down 28.1% in Novembermarketbeat.com - December 14 at 10:39 PMStock Traders Buy Large Volume of Put Options on POINT Biopharma Global (NASDAQ:PNT)marketbeat.com - December 13 at 3:48 PMPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Knowmsn.com - December 8 at 6:24 PMLilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisitionmarkets.businessinsider.com - December 4 at 10:26 AMmarketbeat.com - December 4 at 6:11 AMAnalysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)markets.businessinsider.com - November 30 at 7:53 PMHold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial Stabilitymarkets.businessinsider.com - November 17 at 11:33 AMLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023finance.yahoo.com - November 17 at 11:33 AMmarketbeat.com - November 17 at 6:03 AMPOINT Biopharma Global Stock (NASDAQ:PNT) Earnings Dates and Earning Callsbenzinga.com - November 15 at 12:37 AMLilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharmamarkets.businessinsider.com - November 15 at 12:37 AMPiper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)markets.businessinsider.com - November 15 at 12:37 AMPOINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?benzinga.com - November 14 at 2:34 PMPOINT Biopharma Global: Why The Market Believes That A Second Bidder May Emergeseekingalpha.com - November 14 at 2:11 AMRecap: POINT Biopharma Global Q3 Earningsbenzinga.com - November 13 at 2:12 PMPOINT Biopharma Reports Loss In Q3, Flat With Last Year, A Week After Lilly Agreed To Acquire Itmarkets.businessinsider.com - November 13 at 2:12 PMPOINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlightsfinance.yahoo.com - November 13 at 7:39 AMEli Lilly extends expiration of tender offer to acquire Point Biopharmamsn.com - November 8 at 11:38 PMLilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16markets.businessinsider.com - November 8 at 11:38 PMLilly Announces Extension of Tender Offer to Acquire POINT Biopharmafinance.yahoo.com - November 8 at 6:37 PMPoint Biopharma quickly gains as big holder comes out against Eli Lilly dealmsn.com - November 6 at 3:26 PMHold Rating on POINT Biopharma Global: Prospects, Uncertainties, and Potential of PNT2002markets.businessinsider.com - October 26 at 6:33 PMPiper Sandler Downgrades POINT Biopharma Global (PNT)msn.com - October 24 at 11:37 PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of POINT Biopharma Global, Inc. (PNT)barrons.com - October 19 at 7:36 PMPOINT Biopharma trades through deal price with Eli Lillymsn.com - October 18 at 5:06 PMHold Rating on POINT Biopharma Amid Acquisition Proposal Uncertainties and Potential Risksmarkets.businessinsider.com - October 18 at 12:06 PMRaymond James Downgrades POINT Biopharma Global (PNT)msn.com - October 7 at 3:30 AMPOINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT ...businesswire.com - October 6 at 9:05 PMLilly eyes targeted cancer therapies with $1.4 billion Point Biopharma dealreuters.com - October 5 at 4:23 PMLilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre Marketmarkets.businessinsider.com - October 3 at 5:00 PMCrude Oil Moves Higher; POINT Biopharma Global Shares Jumpmarkets.businessinsider.com - October 3 at 5:00 PMCruise lines, spinoff slumps, Eli Lilly-Point deal: Trending Stocksfinance.yahoo.com - October 3 at 5:00 PMEli Lilly POINTs Toward Radiopharmaceutical Ambitionsseekingalpha.com - October 3 at 1:32 PMEli Lilly and Company: Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapiesfinanznachrichten.de - October 3 at 12:00 PMEli Lilly to acquire Point Biopharma in $1.4B dealseekingalpha.com - October 3 at 12:00 PMShareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lillybenzinga.com - October 3 at 12:00 PMLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapiesfinance.yahoo.com - October 3 at 7:00 AMWill Weakness in POINT Biopharma Global Inc.'s (NASDAQ:PNT) Stock Prove Temporary Given Strong Fundamentals?finance.yahoo.com - September 30 at 1:28 PM Get POINT Biopharma Global News Delivered to You Automatically Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. PNT Media Mentions By Week PNT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PNT News Sentiment▼0.000.43▲Average Medical News Sentiment PNT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PNT Articles This Week▼01▲PNT Articles Average Week Get POINT Biopharma Global News Delivered to You Automatically Sign up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Gyre Therapeutics News Kiniksa Pharmaceuticals News Morphic News Xencor News Akero Therapeutics News Arcus Biosciences News ANI Pharmaceuticals News Verona Pharma News Ligand Pharmaceuticals News Gemini Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PNT) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
